中国8月龄婴儿同时接种肠道病毒71型灭活疫苗与麻风腮疫苗的免疫原性与安全性:一项非劣效随机对照试验
该4期随机开放标签非劣效试验纳入680名8月龄婴儿,比较EV71疫苗与MR疫苗同时接种与分开接种的免疫原性和安全性。同时接种组抗EV71、麻疹、风疹血清阳转率分别为97.9%、97.4%、94.3%,与分开接种组相似,所有抗体非劣效成立。三组不良反应率分别为54.4%、43.9%、52.6%,组间相当。
要点
- 同时接种组抗EV71、麻疹、风疹血清阳转率分别为97.9%、97.4%、94.3%,与分开接种组相似。
- 所有抗体非劣效成立,血清阳转率差值的双侧97.5%CI下限均高于预设的-10%界值。
- 不良反应率同时接种组54.4%、MR组43.9%、EV71组52.6%,组间相当。
核心结论
- 同时接种EV71疫苗与MR疫苗诱导的抗体应答稳健,且非劣效于单独接种。
- 同时接种的反应原性和安全性特征与单独接种相当。
研究设计与样本
- 4期随机开放标签非劣效研究,共纳入680名8月龄婴儿。
- 同时接种组:第0天接种第1剂EV71疫苗和MR疫苗,第28天接种第2剂EV71疫苗。
- EV71组:第0天和第28天分别接种两剂EV71疫苗。
- MR组:第0天接种MR疫苗。
- 第0天和第56天采血,分别测定各抗原的抗体滴度或浓度。
主要发现
- 同时接种组抗EV71、麻疹、风疹血清阳转率分别为97.9%、97.4%、94.3%。
- EV71组抗EV71血清阳转率为99.6%。
- MR组抗麻疹、抗风疹血清阳转率分别为98.4%、98.9%。
- 所有抗体非劣效成立,同时接种组与分开接种组血清阳转率差值的双侧97.5%CI下限均高于预设的-10%界值。
- 不良反应率同时接种组54.4%、MR组43.9%、EV71组52.6%,组间相当。
关键数值与推荐
- 非劣效界值为-10%,以血清阳转率差值的双侧97.5%CI下限高于该界值判定非劣效成立。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To evaluate the immunogenicity and safety of simultaneous administration of the enterovirus 71 (EV71) vaccine with the measles and rubella (MR) combined vaccine. METHODS: In this phase 4, randomized, open-label and noninferiority study, a total of 680 infants aged 8 months were enrolled and assigned to the simultaneous administration group (infants received the first dose of EV71 vaccine and MR vaccine on Day 0, and the second dose of EV71 vaccine on Day 28), or the separate administration groups (EV71 group: infants received two doses of EV71 vaccine on Day 0 and Day 28, respectively; MR group: infants received MR vaccine on Day 0). Blood sample was obtained on Day 0 and Day 56 to measure antibody responses to each of the antigens in terms of antibody titer or concentration, respectively. Local and systemic adverse reactions (ARs) and other adverse events (AEs) following each dose were monitored and compared among groups. RESULTS: After vaccination, simultaneous administration group showed similar seroconversion rates of antibody against EV71(97.9%), measles (97.4%), and rubella (94.3%) compared to EV71 group (99.6% for anti-EV71) or MR group (98.4% for anti-measles and 98.9% for anti-rubella, respectively). Noninferiority was demonstrated for all antibodies as the lower limits of two-sided 97.5% confidence intervals (CIs) of the difference in seroconversion rates between simultaneous administration group and separate administration groups were above the predefined margin of -10%. Additionally, the adverse reaction rates were comparable among groups (54.4% in the simultaneous group versus 43.9% in the MR group versus 52.6% in the EV71 group). CONCLUSION: Antibody responses induced by simultaneous administration of EV71 vaccine with MR vaccine were robust and noninferior to those by single administration alone. Like the previous findings by single administration alone, simultaneous administration demonstrated comparable reactogenicity and safety profiles.
引用
- Zhao Z, Liao Y, Li Y, et al. Immunogenicity and safety of the inactivated enterovirus 71 vaccine administered concomitantly with the measles-rubella vaccine in infants aged 8 months in China: A noninferiority randomized controlled trial. Vaccine. 2022. PMID: 35753838. doi:10.1016/j.vaccine.2022.06.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。